CARISMA Therapeutics (STU:W2J) ROCE % : -116.43% (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is CARISMA Therapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. CARISMA Therapeutics's annualized ROCE % for the quarter that ended in Mar. 2024 was -116.43%.

CARISMA Therapeutics ROCE % Historical Data

The historical data trend for CARISMA Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CARISMA Therapeutics ROCE % Chart

CARISMA Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

ROCE %

-53.76

-106.26

-147.97

-139.00

CARISMA Therapeutics Quarterly Data
	Dec20	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial							-97.91	-66.74	-86.29	-105.94	-116.43

CARISMA Therapeutics ROCE % Calculation

CARISMA Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-81.366	/	( ( (68.112 - 18.568)	+	(82.121 - 14.588) )	/ 2 )
	=	-81.366	/	( (49.544	+	67.533)	/ 2 )
	=	-81.366	/	58.5385
	=	-139.00 %

CARISMA Therapeutics's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-71.796	/	( ( (82.121 - 14.588)	+	(67.891 - 12.09) )	/ 2 )
	=	-71.796	/	( ( 67.533	+	55.801 )	/ 2 )
	=	-71.796	/	61.667
	=	-116.43 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

CARISMA Therapeutics (STU:W2J) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

CARISMA Therapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of CARISMA Therapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

CARISMA Therapeutics (STU:W2J) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CARISMA Therapeutics Inc (STU:W2J) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

CARM:USA W2J:Germany

Address

245 First Street, Suite 1800, Cambridge, MA, USA, 02142

Website

https://www.carismatx.com

CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.

CARISMA Therapeutics (STU:W2J) Headlines

No Headlines